Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Myelodysplastic Syndrome
100%
Paroxysmal Nocturnal Hemoglobinuria
93%
Overall Survival
86%
Acute Myeloid Leukemia
86%
Azacitidine
57%
Hematopoietic Stem Cell Transplantation
45%
Oral
39%
Multiple Myeloma
39%
Aplastic Anemia
38%
Decitabine
37%
Hemoglobin
34%
Thromboembolism
27%
Monotherapy
26%
Observational Study
26%
Platelet
26%
Lactate Dehydrogenase
25%
Idiopathic Thrombocytopenic Purpura
24%
Chemotherapy
24%
Adverse Event
22%
Hematopoietic Cell
21%
Anemia
21%
High Risk Population
19%
Infection
19%
Predictive Factor
19%
Romiplostim
18%
Karyotype
18%
Acute Lymphoblastic Leukemia
18%
Myeloproliferative Neoplasm
18%
Diseases
18%
International Prognostic Scoring System
18%
Allogeneic Hematopoietic Stem Cell Transplantation
17%
Survival Rate
17%
Cyclosporine
17%
Neoplasm
17%
Chronic Myelomonocytic Leukemia
16%
Hematologic Malignancy
15%
Hazard Ratio
15%
Eculizumab
15%
Prognostic Factor
15%
Clinical Significance
15%
Hemolysis
15%
Immunosuppressive Treatment
14%
Clinical Trial
14%
Acute Myelogenous Leukemia
13%
Cisplatin
13%
Arm
13%
Multivariate Analysis
13%
Malignant Neoplasm
13%
Cell Transplantation
13%
Febrile Neutropenia
13%
Pharmacology, Toxicology and Pharmaceutical Science
Paroxysmal Nocturnal Hemoglobinuria
49%
Acute Myeloid Leukemia
49%
Myelodysplastic Syndrome
47%
Remission
29%
Overall Survival
28%
Aplastic Anemia
27%
Decitabine
24%
Diseases
22%
Adverse Event
21%
Chemotherapy Regimen
20%
Acute Lymphoblastic Leukemia
20%
Azacitidine
19%
Micafungin
18%
Hemoglobin
17%
Placebo
15%
Monotherapy
15%
Observational Study
14%
Hematologic Malignancy
13%
Clinical Trial
13%
Lactate Dehydrogenase
12%
Romiplostim
12%
Eltrombopag
12%
Antifungal Therapy
12%
Itraconazole
12%
Febrile Neutropenia
12%
Immunosuppressive Agent
11%
Minimal Residual Disease
11%
Hemolysis
11%
Thrombocytopenia
10%
Antifungal Agent
10%
Daunorubicin
9%
Malignant Neoplasm
9%
Neoplasm
9%
Cytopenia
9%
Disease Course
8%
Cytarabine
8%
Thromboembolism
8%
Leukemia
7%
Tolerability
7%
Retrospective Study
7%
Anemia
7%
Ciclosporin
7%
Epidemiology
6%
Hematologic Disease
6%
Antibiotics
6%
Systemic Mycosis
6%
Secondary Acute Myeloid Leukemia
6%
Multiple Myeloma
6%
Thymocyte Antibody
6%
Venetoclax
6%
Immunology and Microbiology
Overall Survival
62%
Myeloid
54%
Allogeneic Hematopoietic Stem Cell Transplantation
49%
Multiple Myeloma
28%
Hematopoietic Cell
28%
Hemoglobin Blood Level
26%
Karyotype
25%
Aplastic Anemia
24%
Lactic Acid
23%
Cell Transplantation
21%
Infectious Disease
18%
Infection
18%
Hemoglobin
16%
Hematopoietic Stem Cell Transplantation
15%
Erythrocyte
15%
Anti-Thymocyte Globulin
14%
Ciclosporin
14%
Granulocyte
13%
Eculizumab
12%
CD34
12%
CCAAT Enhancer Binding Protein Alpha
12%
Romiplostim
12%
Hepatitis B Virus
12%
Autologous Peripheral Blood Stem Cell Transplantation
12%
Platelet
10%
High Risk Population
9%
Cytomegalovirus
9%
Immunosuppressive Therapy
9%
Recurrence Free Survival
8%
Chronic Graft Versus Host Disease
8%
Lactate
7%
Low Drug Dose
7%
Platelet Count
7%
Cytomegalovirus Infection
7%
Immunocompromised Patient
7%
Cell Count
7%
Viral Load
7%
B Cell
6%
Progression Free Survival
6%
Aspergillosis
6%
Lung
6%
Blinatumomab
6%
Phosphatase
6%
Precursor
6%
Epoetin Beta
6%
Middle East Respiratory Syndrome Coronavirus
6%
Blood Level
6%
Multidrug Resistance
6%
Galectin 3
6%
positron emission tomographic scan
6%